Prime Therapeutics Announces Participation in URAC Accreditation

ST. PAUL, Minn., June 18 /PRNewswire/ — Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, announced today their participation in URAC’s efforts to create a pharmacy benefit management (PBM) accreditation program for the commercial markets.

This PBM accreditation program is designed to encourage industry best practices, promote quality improvement and protect and empower consumers. Prime has begun participation in URAC’s beta testing process and is currently working toward accreditation. Prime expects URAC to issue the final standard in July. “We are delighted to be making a proactive effort in identifying opportunities to improve and promote standard practices in the PBM industry,” says Prime’s Chief Medical Officer and Senior Vice President, Dr. James Hartert. “As a pioneer in transparency and disclosure, we have a long-term history of commitment to high quality business practices and the promotion of member health.”

URAC’s standards address a range of industry practices including: organizational integrity, customer service/communications/disclosure, pharmacy distribution channels, formulary/pharmacy and therapeutics, and drug utilization management. Prime is one of several PBMs and health plans participating in the beta accreditation process.

URAC, an independent, non-profit organization, is a leader in promoting health care quality through accreditation and certification programs. URAC’s standards keep pace with the rapid changes in the health care system and provide a mark of distinction for health care organizations to demonstrate their commitment to quality and accountability.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 12.5 million covered lives, its client base includes 10 Blue Cross and Blue Shield Plans, employer and union groups and thirdparty administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com/.

Prime Therapeutics

CONTACT: Jenna Thompson of Prime Therapeutics, +1-651-846-8461,jthompson@primetherapeutics.com

Web site: http://www.primetherapeutics.com/